Children who had nuchal translucency thickening during the first trimester, but a normal karyotype and no structural abnormalities, are clinically and developmentally normal during the first 2 years of life, according to a study in the January issue of the American Journal of Obstetrics & Gynecology.
Children who had nuchal translucency thickening during the first trimester, but a normal karyotype and no structural abnormalities, are clinically and developmentally normal during the first 2 years of life, according to a study in the January issue of the American Journal of Obstetrics & Gynecology.
Yves Ville, MD, of the Paris-Ile-de-France-Ouest Medical School in Paris, France, and colleagues identified 248 fetuses with nuchal translucency in the 99th percentile or greater at 11 to 14 weeks' gestation. Long-term outcomes were examined in 160 children who were born alive. Outcomes were assessed by clinical examination and the Ages and Stages Questionnaire and compared with 370 term control children.
After 2 years, the researchers found no association between nuchal translucency thickness and clinical or developmental abnormalities, or any increase in the incidence of developmental delay.
Senat MV, Bussieres L, Couderc S, et al. Long-term outcome of children born after a first-trimester measurement of nuchal translucency at the 99th percentile or greater with normal karyotype: a prospective study. Am J Obstet Gynecol. 2007;196:53. e1-6.
Link between prenatal air pollution and reduced lung function in offspring reported
July 25th 2024Higher prenatal exposure to PM2.5 pollution is associated with reduced lung volume and airflow limitation in children, highlighting the critical impact of air pollution on in utero lung development.
Read More
Cut costs observed from out-of-home care in children with prenatal substance exposure
July 24th 2024A recent study reveals that while children exposed to maternal substance use face higher hospital costs up to age 20 years, out-of-home care significantly mitigates this financial burden.
Read More
Global progress in neonatal tetanus elimination from 2000 to 2022
July 18th 2024Incorporating maternal and neonatal tetanus elimination strategies into national immunization activities is crucial for sustaining elimination and reducing neonatal mortality worldwide, as highlighted by the latest CDC report.
Read More
PreTRM test shows efficacy in reducing severe neonatal morbidity and mortality
July 18th 2024The PreTRM test, a blood-based biomarker test for predicting preterm birth risk, has demonstrated significant efficacy in lowering severe neonatal morbidity and mortality, as reported by Sera Prognostics Inc.
Read More